PMID- 19669304
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20240322
IS  - 1936-0533 (Print)
IS  - 1936-0541 (Electronic)
IS  - 1936-0533 (Linking)
VI  - 2
IP  - 2
DP  - 2008 Jun
TI  - A randomized controlled pilot study of Pentoxifylline in patients with 
      non-alcoholic steatohepatitis (NASH).
PG  - 196-201
LID - 10.1007/s12072-008-9058-1 [doi]
AB  - PURPOSE: Tumor necrosis factor-alpha (TNF-alpha) is implicated in non-alcoholic 
      steatohepatitis (NASH). Pentoxifylline inhibits TNF-alpha. We wanted to evaluate 
      the efficacy of Pentoxifylline on NASH patients. METHODS: Patients with biopsy 
      proven NASH and persistently elevated alanine aminotransferase (ALT) greater than 
      1.5 times the upper limit of normal were randomized to 3 months of treatment with 
      a step 1 American Heart Association diet and daily exercise with Pentoxifylline 
      or placebo. Liver function tests, serum lipids and TNF-alpha, Interleukin 6 
      (IL-6), and plasma hyaluronic acid were measured at baseline, at weeks 6 and 12. 
      Categorical data were analyzed by Fisher's exact test while independent sample 
      t-test and Mann-Whitney test were used for continuous data. RESULTS: Eleven 
      patients were randomized into the Pentoxifylline and nine to the placebo group. 
      After 3 months of treatment body mass index (BMI), ALT and aspartate 
      aminotransferase (AST) decreased significantly in both groups. There was no 
      difference between the two groups in reduction of BMI (P = 0.897). There was 
      significantly greater reduction in AST in the Pentoxifylline group (P = 0.038). 
      There was a trend toward lower ALT level (P = 0.065) in the Pentoxifylline group. 
      TNF-alpha and IL-6 decreased significantly in both groups after treatment, but 
      there was no significant difference between the two groups. CONCLUSION: Three 
      months of Pentoxifylline treatment in combination with diet and exercise results 
      in significantly greater reduction in AST levels in patients with NASH as 
      compared with controls.
FAU - Lee, Yin-Mei
AU  - Lee YM
AD  - Department of Gastroenterology/Hepatology, National University Hospital, 5 Lower 
      Kent Ridge Road, Singapore, 119074, Singapore, mdcleeym@nus.edu.sg.
FAU - Sutedja, Dede S
AU  - Sutedja DS
FAU - Wai, Chun-Tao
AU  - Wai CT
FAU - Dan, Yock-Young
AU  - Dan YY
FAU - Aung, Myat-Oo
AU  - Aung MO
FAU - Zhou, Lei
AU  - Zhou L
FAU - Cheng, Chee-Leong
AU  - Cheng CL
FAU - Wee, Aileen
AU  - Wee A
FAU - Lim, Seng-Gee
AU  - Lim SG
LA  - eng
PT  - Journal Article
DEP - 20080228
PL  - United States
TA  - Hepatol Int
JT  - Hepatology international
JID - 101304009
PMC - PMC2716847
EDAT- 2008/06/01 00:00
MHDA- 2008/06/01 00:01
PMCR- 2008/06/01
CRDT- 2009/08/12 09:00
PHST- 2007/08/31 00:00 [received]
PHST- 2008/01/24 00:00 [accepted]
PHST- 2009/08/12 09:00 [entrez]
PHST- 2008/06/01 00:00 [pubmed]
PHST- 2008/06/01 00:01 [medline]
PHST- 2008/06/01 00:00 [pmc-release]
AID - 9058 [pii]
AID - 10.1007/s12072-008-9058-1 [doi]
PST - ppublish
SO  - Hepatol Int. 2008 Jun;2(2):196-201. doi: 10.1007/s12072-008-9058-1. Epub 2008 Feb 
      28.